DSS Statistics Seminar
May 13, 2022, 17:00
https://uniroma1.zoom.us/j/86881977368?pwd=SWRFcVFjMDZTa0lXZk05TE1zNm5adz09
Passcode: 432940

Bayesian Statistics applied to Early "Oncology Drug Development"

Roberto Bugarini
Head of Oncology Biostatistics (ECD), Pfizer, San Diego, CA, USA

Ray Li
Director of Biostatistics (ECD), Pfizer, Cambridge, MA, USA

Oncology dose finding studies, in general, aim at determining the maximum tolerated dose (MTD) reflecting the desire to treat patients who have limited options under the assumption that higher drug doses will have better therapeutic activity. We are describing different methods (ie 3+3, mTPI, mTPI-2, and BLRM). This seminar will feature speakers from Pfizer Inc., to share their insights and the recent statistical innovations to address the challenges.

In addition to safety evaluation, Early Sign of Efficacy (ESOE) is a critical step in all early clinical programs to extend the development of a molecule or not. Robust and consistent calculation of the probability of making the right decision is critical. Innovative methodologies are needed to optimize these calculations and ensure all molecules are assessed in the same way across the oncology portfolio.

Case studies will be discussed for dose finding and the utilization of Bayesian statistics in ESOE evaluation.

SAPIENZA
UNIVERSITÀ DI ROMA